Skip to content

Follow-up of patients hospitalized with COVID-19 in the northwest region of Paraná.

Clinical and Immunological Surveillance of hospitalized patients with COVID-19 in the Northwest macro-region of the State of Paraná -

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-8xfsjsc
Enrollment
Unknown
Registered
2022-08-23
Start date
2022-05-17
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Screening intervention

Interventions

In the CEP substantiated opinion number 5,282,299, the study begins with the objective of making an understandable exploration of 50 participants hospitalized with the diagnosis of COVID-19. This is a

Sponsors

GlucoScan Whatch
Lead Sponsor
Universidade Estadual de Maringá
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants aged 18 or over; both genders; non pregnant

Exclusion criteria

Exclusion criteria: Worsening of the disease; ICU admission, intubation or any other factor that may occur; pregnant women; death

Design outcomes

Primary

MeasureTime frame
Expected Outcome 1: Thus, considering a margin of error of approximately 5%, a significance level of 95%, which implies a z-score of 1.96. The sample size sufficient to determine an accuracy (proportion p) of 90%, which was obtained in the pre-clinical stage of the study, the calculated N was 103, the result also being in agreement with the study by A`Hern (2001). ), which presents tables for the minimum size for trials in this phase, based on the exact binomial distribution, instead of approximations by the normal, considering a confidence level of 95% and power of 90%;Outcome found 1: All recommended criteria were maintained, from sample size calculation to data analysis, it can be verified that the results reached the desired effectiveness for a screening test. The consistency of the results can be verified throughout the development of the study, due to its precision and accuracy, as well as confidence intervals and hypothesis tests to verify the statistical significance of the accuracy obtained, which remained above 92% in all study days. It can be observed that the sensitivity, precision and PPV were always above 94%, with specificity above 90% on most days, while the NPV was between 80 and 90% during all days, which is quite adequate for a screening test

Secondary

MeasureTime frame
Were not observed

Countries

Brazil

Contacts

Public ContactJoão Sedovski

GlucoScan Whatch

sedovski@gmail.com(+55)44997685483

Outcome results

None listed

Source: REBEC (via WHO ICTRP)